Achieving these goals involves the use of disease‐modifying therapy, that is, the ‘fantastic four’ in patients with reduced left ventricular ejection fraction (LVEF), in addition to sodium–glucose cotransporter 2 (SGLT2) inhibitors in HF with preserved LVEF, which have demonstrated efficacy across the entire range of LVEF. Here, SLC5A2 is linked to hydrops fetalis.